Target intelligence / Profile preview

Alpha-amylase enzyme (α-amylase (sometimes abbreviated as AAM or AMY))

Target
α-amylase (sometimes abbreviated as AAM or AMY)
Molecular classification
Enzyme, Glycoside hydrolase family 13, Metalloenzyme (calcium-dependent)
01

Overview

Alpha-amylase is a calcium-dependent metalloenzyme that catalyzes the endohydrolysis of internal α-(1→4)-D-glucosidic linkages in large polysaccharides such as starch and glycogen, producing smaller sugars like maltose and dextrins.[5][6] It is widely distributed among living organisms; in humans it exists primarily as two isoenzymes—salivary alpha-amylase ("ptyalin") produced by salivary glands for initial carbohydrate digestion in the mouth, and pancreatic alpha-amylase secreted into the small intestine for further breakdown during digestion.[6][2] The enzyme has a characteristic three-domain structure with an eight-stranded α/β barrel catalytic domain containing key acidic residues essential for its function.[1][5] Alpha-amylases play a crucial role in nutrition by enabling efficient energy extraction from dietary carbohydrates. Clinically, serum amylase measurement serves as an important diagnostic marker for acute pancreatitis.[2] Pharmacologically, inhibition of this enzyme is targeted to manage postprandial hyperglycemia in diabetes mellitus through drugs like acarbose that competitively block its active site.[5][3]

Other names
4-α-D-glucan glucanohydrolasePtyalin (for salivary alpha-amylase)Pancreatic amylaseEC 3.2.1.1
02

Mechanism of action

Competitive inhibition of the active site to reduce enzymatic breakdown of dietary starches, thereby lowering postprandial blood glucose spikes

03

Biological functions

Carbohydrate digestion (hydrolysis of starch and glycogen)Production of maltose, dextrins, and oligosaccharides from polysaccharidesRegulation of postprandial glucose levels
04

Disease associations

Diabetes mellitus (targeted for glycemic control)Acute pancreatitis and other pancreatic disorders (as a biomarker)Salivary gland disorders
05

Safety considerations

Gastrointestinal side effects with inhibitors such as acarbose or miglitol, including flatulence, diarrhea, abdominal discomfort due to undigested carbohydrates reaching the colon.Risk of hypoglycemia when used in combination with other antidiabetic agents.
06

Interacting drugs

Acarbose

1 more in the full profile.

07

Biomarkers

Serum amylase levels for diagnosis/monitoring of acute pancreatitis and other pancreatic diseases

Beyond the preview

Go deeper on Alpha-amylase enzyme (α-amylase (sometimes abbreviated as AAM or AMY)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-amylase enzyme (α-amylase (sometimes abbreviated as AAM or AMY)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call